Goldman Sachs-backed biotech firm Attovia is seeking $212.5 million in a US IPO, signaling ongoing appetite for healthcare listings amid cautious equity markets.
Goldman Sachs (GS) is named as the backer of Attovia's $212.5 million US IPO. The firm is expected to earn underwriting fees, contributing incrementally to equity capital markets revenue. While the deal is small relative to GS's overall franchise, it reinforces its leading position in biotech IPOs.
Underwriting fees for a $212.5 million IPO typically range from 4–7% of the deal size, translating to a potential $8–15 million, though precise fees aren’t disclosed.
Individually, the deal is immaterial to Goldman’s overall earnings, but it adds to a growing pipeline of ECM transactions that contribute to quarterly advisory and underwriting revenue.
Attovia, a biotech company backed by Goldman Sachs, has filed for a $212.5 million initial public offering in the United States. The deal highlights a continuing revival in biotech IPOs, with Goldman Sachs capturing advisory fees. The offering's size and sector suggest moderate demand for new healthcare listings despite broader market volatility.
Attovia is a biotech company, though specific therapeutic areas or pipeline details were not disclosed in the initial IPO filing report.
Goldman Sachs is serving as the lead underwriter, reflecting its strong presence in healthcare equity capital markets and its role in bringing biotech firms to public markets.
The filing indicates continued interest in biotech IPOs despite a mixed broader market, with investors still willing to allocate capital to the sector at appropriate valuations.